Michael R. Jacobs, MD, PhD Roslyn Yomtovian, MD

Slides:



Advertisements
Similar presentations
Experience of the Irish Blood Transfusion Service William G. Murphy MD
Advertisements

Update on the AABB Standards and platelet bacterial contamination TAC: MVRBC 2011.
Bacteriological Examination of water, milk and air
URINARY TRACT INFECTION
Ex. 14: Skin Cultures and Importance of Selective and Differential Media for Isolating Gram-Positive Cocci Objectives??
Eye Spy: Microbial Growth on Contact Lenses Theresa Edson and Kyle Hilsabeck Introduction: Biofilms are “organized microbial systems consisting of layers.
Blood Culture. Bacteremia: Types  Transient: Disruption of mucosal surfaces (dental or surgical procedures)  Intermittent: Associated with abscesses.
Comparison of Bacterial Etiology of Infectious Corneal Ulcers in Contact Lens Wearers and Non-Contact Lens Wearers at the University of Chicago Shuchi.
Amylase Production (Starch Hydrolysis Test)
Micro labs - review BIOL260 Winter Ubiquity What organisms grow best at room temperature? ___°C? At body temperature? = ___°C? What kind of medium.
Wound infections.
Neonatal Sepsis and Recent Challenges Mohammad Khasswneh, MD Assistant Professor of Pediatrics JUST.
Efficacy of Disinfection during Long-Term Storage of Contact Lenses Pauline Cho 1, Maureen Boost 2, Angel Lee School of Optometry; 2. Dept of Health.
Comparison of the Diagnostic Value of the Standard Tube Agglutination Test and the ELISA IgG and IgM in Patients with Brucellosis Presented by Dr. Md.
Only 5-15% of blood cultures are (+) in febrile patients A.Types of bacteremia: Extravascular via the lymphatic's Intravascular: i.e. CVC infections B.Types.
MRSA and VRE. MRSA  1974 – MRSA accounted for only 2% of total staph infections  1995 – MRSA accounted for 22% of total staph infections  2004 – MRSA.
Gram Stains of Bacteria
MRSA and VRE. MRSA  1974 – MRSA accounted for only ____of total staph infections  1995 – MRSA accounted for _____ of total staph infections  2004 –
Microbiological Considerations in Diagnosing S. aureus Bacteremia Patrick R. Murray, Ph.D. NIH Clinical Center Chief, Microbiology Laboratories.
Microbial Testing of Cell Therapy Products Summary of NIH Clinical Center Studies Elizabeth Read MD Chief, Cell Processing Section Department of Transfusion.
2 pt 3 pt 4 pt 5pt 1 pt 2 pt 3 pt 4 pt 5 pt 1 pt 2pt 3 pt 4pt 5 pt 1pt 2pt 3 pt 4 pt 5 pt 1 pt 2 pt 3 pt 4pt 5 pt 1pt Bacterial Counts Oxygen and Temperature.
Isolation and Characterization of MRSA at UW-Eau Claire Hannah Stage, Hannah Samuel and  Faculty Mentor Dr. Sasha Showsh  Biology  University of Wisconsin-Eau.
Dr Anand Deshpande P D Hinduja National Hospital & MRC Mumbai.
NOSOCOMIAL INFECTIONS Phase 1: Testing the efficacy of Nano-Mg (OH) 2 Dorothea A. Dillman PhD, RN, CCRN, LNC.
Katherine Gerrald, PharmD Candidate 1 ; Anne Hishon, PharmD Candidate 1 ; P. Brandon Bookstaver, PharmD, BCPS 2 1 University of South Carolina, College.
1 Verax Biomedical Platelet PGD ® Test. 2 Verax Biomedical Platelet PGD ® Test Results in approximately 30 minutes Designed for use with LR or non-LR:
SPM 100 Clinical Skills Lab 1 Standard Precautions Sterile Technique Daryl P. Lofaso, M.Ed, RRT.
Bacterial Screening of Platelet Concentrates by Real-Time PCR Theo Cuypers 1 also on behalf of, H.W. Reesink 1,3 I.G.H. Rood 1,2 T. Mohammadi¹, ²P.H.M.
Plasmid maintenance Maintaining plasmids and expressing those genes is energetically expensive to a bacterial cell. It is beneficial only if the bacteria.
Comparison of the diagnostic value of STA test and ELISA IgG and IgM in patients with Brucellosis Mustafa Ertek, Halil Yzgi, Zulal Ozkart et al. Turk.
LAB NO 8 LAB NO 8 Environmental Factors Affecting Microbial growth.
Validating the Micro PRO™ Technology. Overview of Today’s Presentation Validation Resources Micro PRO™ Applications and Corresponding Validation Parameters.
Bacterial Infection of Cardiovascular system By Dr. Humodi A. Saeed Associate Prof. of Medical Microbiology College of Medical Laboratory Science Sudan.
Comparison of the Systemic Inflammatory Response Syndrome between Monomicrobial and Polymicrobial Pseudomonas aeruginosa Nosocomial Bloodstream Infections.
Antibacterial Inhibition of Common Cooking Spices Against Escherichia coli Mariah Weir Department of Biological Sciences, York College of Pennsylvania.
PHT 313 Lab (1) Staphylococci.
Welcome To Journal Club Presented by: Dr. Aminul Islam Lecturer of Microbiology, MMC.
A Comparison of Staphylococcus aureus Isolates from Laboratories LS 203 and LS 224 at York College of Pennsylvania Introduction Staphylococcus aureus causes.
Comparison of the diagnostic value of STA test and ELISA IgG and IgM in patients with Brucellosis Mustafa Ertek, Halil Yzgi, Zulal Ozkart et al. Turk J.
SPM 100 Skills Lab 1 Standard Precautions Sterile Technique Daryl P. Lofaso, M.Ed, RRT Clinical Skills Lab Coordinator.
© 2009 CSTS: The Cardiovascular Surgical Translational Study Using the Centers for Disease Control and Prevention’s National Healthcare Safety Network.
313 PHT LAB#1 ☠ Lab coat & marker. ☠ No eating, drinking, ☠ Benches disinfection. ☠ Inoculating loop sterilization. ☠ Aseptic technique. ☠ Discarded.
1 BacTx ™ Kit for Detection of Bacterial Contamination of Platelets Andrew E. Levin, Ph.D. Immunetics, Inc. Blood Products Advisory Council Meeting March.
(Wounds, Abscesses, Burns, Sinuses)
Significance of Case Style in the Transfer of Pseudomonas aeruginosa to Contact Lenses During Storage Linda M. Ellis Department of Biology, York College.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
ANALYTICAL PROCESS CONTROL
Urinary Tract Infection Department of Microbiology
Bacterial Infection of Wound
Ear culture D. M. M. Lab..
Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA
FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.
Biochemical Activities of Microorganisms Part (1)
Automated Blood Cultures 韩向阳 Xiang-Yang Han, MD, PhD Department of Laboratory Medicine The University of Texas M. D. Anderson Cancer Center.
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Investigating extracellular Enzymes of microorganisms.
PHT 226 Lab no 9. MIC: It is the lowest concentration of the antimicrobial agent that inhibits the growth of the test organism but not necessarily kills.
CONCLUSIONS Amended Abstract Detection of GBS Directly from ESwab Collected Samples Using the BD MAX™ GBS Assay Suzane Silbert, Talita T. Rocchetti, Alicia.
MALDI TOF analysis of Streptococcus pneumoniae from Cerebrospinal Fluid for the diagnosis of Acute Bacterial Meningitis Dr. R. Ravikumar, M.D., Professor.
Effects of omadacycline on gut microbiota populations and Clostridium difficile germination, proliferation and toxin production in an in vitro model of.
PHT 313 Lab (1) Staphylococci.
Antibiotics Basmah almaarik
Microbial Growth Growth in Batch Culture
1 A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital DIABETES Care; Aug 2006; 29,8 : FM R1 임혜원.
Lab # 1. Antimicrobial Therapy  Natural antibiotic agents:  Produced by microorganisms:  Penicillium notatum – penicillin  Semi-synthetic antibiotic.
CRICOS Provider Code: 01505M RTO Number: 3045 VBP035 Perform Microbiological Procedures in the Food Industry DHS V
Microbiology lab Urinary system. Urine culture steps 1.Collect the sample in sterile container: 1.Midstream catch. 2.Through a catheter. 3.Suprapubic.
Detection of bacteria in blood products
P. Moreillon, J.M. Entenza  Clinical Microbiology and Infection 
Streaking an Agar Plate For
Presentation transcript:

Bacterial Contamination of Platelets Experience at University Hospitals of Cleveland, 1991-2005 Michael R. Jacobs, MD, PhD Roslyn Yomtovian, MD Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio

Disclosures Drs Yomtovian and Jacobs have received funding as investigators at Case Western Reserve University and University Hospitals of Cleveland to investigate bacterial contamination of platelets from Gambro, Hemosystem, Immunetics, Pall Corporation, and Verax Travel expenses for our attendance at this meeting are being paid by University Hospitals of Cleveland Dr Yomtovian is an advisor to Verax and Immunetics

Bacterial Contamination of Platelet Pools Ohio, 1991 From June 27 through July 30, 1991, four episodes of bacterial contamination of platelet pools occurred in an Ohio hospital and were reported by the hospital through the Food and Drug Administration (FDA) to CDC. This report summarizes the results of the epidemiologic investigation of these episodes. http://www.cdc.gov/mmwr/preview/mmwrhtml/images/ic_wk.gif January 24, 1992 / 41(03);36-37 (Zaza, Tokars, Yomtovian et al. Infect Cont Hosp Epidemiol 1994;15:82-87).

Case Definition and Methods Isolation of an organism from an aliquot of a platelet product obtained at time of issue by plate culture of 0.1 ml on a blood agar plate incubated in 5% CO2 for up to 48 h PLUS Repeat isolation of the same organism from the same source (aliquot and/or nearly empty unit retained at 4ºC), and, in the case of RDP pools, from the remnants of one of the RDPs (retained at 4ºC) used to make up the pool Quantitative plate cultures of serial 1-in-10 dilutions of all products with initial bacterial growth were performed

Bacterial species 1991-2005, N=46 Active surveillance VGS+CoNS (1) 1 2 3 4 1991/2 1991/4 1992/2 1992/4 1993/2 1993/4 1994/2 1994/4 1995/2 1995/4 1996/2 1996/4 1997/2 1997/4 1998/2 1998/4 1999/2 1999/4 2000/2 2000/4 2001/2 2001/4 2002/2 2002/4 2003/2 2003/4 2004/2 2004/4 2005/2 2005/4 Year/quarter VGS+CoNS (1) S. uberis (1) S. bovis (2) S. marcescens (2) S. aureus (5) B. cereus (2) P. aeruginosa (2) CoNS (31) Active surveillance Passive surveillance Active surveillance Data from: CDC. 1992. Morb Mortal Wkly Rep 41:36-37. Yomtovian, R, et al.. Transfusion 2006, in press. Zaza S, et al. Infect Control Hosp Epidemiol 1994;15(2):82-7. Yomtovian, R, Jacobs, M. 2006. Unpublished data Sapatnekar S, et al.. Transfusion 2001;41(11):1426-30.

Bacterial contamination of platelets – Cleveland 1991-2005, N=46 RDP units 35 SDP units: 11 Age at issue: 2-3 d 6 4-5 d 40 Detected by active surveillance 43 Detected by passive surveillance 3

Number of instances and rates of bacterial contamination detected by active surveillance, and number of cases and rates of transfusion reactions and bacteremia for platelet transfusions by transfusion episode and by platelet unit for all platelet transfusions SDP units RDP – per unit RDP - per pool All transfusionsc No. of cases (rate) P valuea P valueb Bacterial contaminationd 7/15,493 (1:2,213) 31/64,805 (1:2,090) 0.89 31/12,961 (1:418) <0.001 38/28,454 (1:749) Contaminated units transfusede 6/48,067 (1:8,011) 26/168,216 (1:6,470) 0.68 26/33,637 (1:1,294) 32/81,704 (1:2,556) Transfusion reactione 3/48,067 (1:16,022) 10/168,216 (1:16,822) 0.75 10/33,637 (1:3,364) 0.01 13/81,704 (1:6,285) Bacteremiae 1/48,067 (1:48,067) 6/168,216 (1:28,036) 0.66 6/33,637 (1:5,606) 0.02 7/81,704 (1:11,672) a P value by Fisher exact method for RDP units compared to SDP units b P value by Fisher exact method for RDP pools compared to SDP units c Based on total of SDP unit and RDP pool transfusions d Numerators used for these calculations are the number of cases detected by active surveillance, while denominators are the numbers of platelet units and/or pools cultured during active surveillance e Numerators used for these calculations are the number of cases detected by active and passive surveillance, while denominators are the number of platelet units and/or pools transfused. Note that 7 of the 38 contaminated units identified by active surveillance were not transfused, while the contaminated unit detected by passive surveillance is included in these calculations, resulting in transfusion of 32 contaminated units. R. Yomtovian, E. Palavecino, A. Dysktra, K. A. Downes, A. Morrissey, S. Bajaksouzian, M. Pokorny, H. M. Lazarus , M.R. Jacobs. Evolution of Surveillance Methods for Detection of Bacterial Contamination of Platelets in a University Hospital, 1991-2004. Transfusion 2006, in press.

Detection by Gram stain, N=39 101 103 105 107 109 1011 negative rare 1+ 2+ 3+ 4+ Bacterial count (CFU/mL) Gram stain result Platelet products were interdicted before use by detection of a positive Gram stain in 6 instances: 8 X 106 to 4 X 1011 cfu/ml of coagulase-negative staphylococci were isolated from these products R. Yomtovian, E. Palavecino, A. Dysktra, K. A. Downes, A. Morrissey, S. Bajaksouzian, M. Pokorny, H. M. Lazarus , M.R. Jacobs. Evolution of Surveillance Methods for Detection of Bacterial Contamination of Platelets in a University Hospital, 1991-2004. Transfusion 2006, in press.

Bacterial species and load vs. transfusion reaction 1991-2004, N=32* 0.0 1.0 2.0 3.0 4.0 5.0 6.0 CONS (2) CONS (4) S. aureus VGS + CONS S. uberis CONS S. marcescens S. bovis B. cereus P. aeruginosa S. aureus (MRSA) No reaction Pos blood cult or leukocytosis Fever, hypotension, death Hypotension or Tx stopped Fever, chills, rigors xx Bacterial count (cfu/ml) 16 3 6 4 *R. Yomtovian, E. Palavecino, A. Dysktra, K. A. Downes, A. Morrissey, S. Bajaksouzian, M. Pokorny, H. M. Lazarus , M.R. Jacobs. Evolution of Surveillance Methods for Detection of Bacterial Contamination of Platelets in a University Hospital, 1991-2004. Transfusion 2006, in press.

Bacterial species and load vs. transfusion reaction 1991-2005, N=38 0.0 1.0 2.0 3.0 4.0 5.0 6.0 CONS (2) CONS (4) S. aureus VGS + CONS S. uberis CONS S. marcescens S. bovis B. cereus P. aeruginosa S. aureus (MRSA) No reaction Pos blood cult or leukocytosis Fever, hypotension, death Hypotension or Tx stopped Fever, chills, rigors xx Bacterial count (cfu/ml) Index cases 2005 cases 2005 case 18 4 7 6 3 bacteremia

Bacterial species and load vs. transfusion reaction 1991-2005, N=38 A system with a sensitivity of 105 cfu/ml would detect 10/11 (91%) serious reactions and 15/19 (79%) of all reactions 1.0E+00 1.0E+01 1.0E+02 1.0E+03 1.0E+04 1.0E+05 1.0E+06 1.0E+07 1.0E+08 1.0E+09 1.0E+10 1.0E+11 1.0E+12 0.0 1.0 2.0 3.0 4.0 5.0 6.0 CONS (2) CONS (4) S. aureus VGS + CONS S. uberis CONS S. marcescens S. bovis B. cereus P. aeruginosa S. aureus (MRSA) No reaction Pos blood cult or leukocytosis Fever, hypotension, death Hypotension or Tx stopped Fever, chills, rigors xx Bacterial count (cfu/ml) 18 4 7 6 3 bacteremia 18 4 7 6 3

Bacterial species and load vs. transfusion reaction 1991-2005, N=38 A system with a sensitivity of 104 cfu/ml would detect all 11 serious reactions and 16/19 (84%) of all reactions 1.0E+00 1.0E+01 1.0E+02 1.0E+03 1.0E+04 1.0E+05 1.0E+06 1.0E+07 1.0E+08 1.0E+09 1.0E+10 1.0E+11 1.0E+12 0.0 1.0 2.0 3.0 4.0 5.0 6.0 CONS (2) CONS (4) S. aureus VGS + CONS S. uberis CONS S. marcescens S. bovis B. cereus P. aeruginosa S. aureus (MRSA) No reaction Pos blood cult or leukocytosis Fever, hypotension, death Hypotension or Tx stopped Fever, chills, rigors xx Bacterial count (cfu/ml) 18 4 7 6 3 bacteremia 18 4 7 6 3

Bacterial species and load vs. transfusion reaction 1991-2005, N=38 A system with a sensitivity of 103 cfu/ml would detect all 11 serious reactions, 18/19 (95%) of all reactions, and 30/38 (79%) of all cases 1.0E+00 1.0E+01 1.0E+02 1.0E+03 1.0E+04 1.0E+05 1.0E+06 1.0E+07 1.0E+08 1.0E+09 1.0E+10 1.0E+11 1.0E+12 0.0 1.0 2.0 3.0 4.0 5.0 6.0 CONS (2) CONS (4) S. aureus VGS + CONS S. uberis CONS S. marcescens S. bovis B. cereus P. aeruginosa S. aureus (MRSA) No reaction Pos blood cult or leukocytosis Fever, hypotension, death Hypotension or Tx stopped Fever, chills, rigors xx Bacterial count (cfu/ml) 18 4 7 6 3 bacteremia 18 4 7 6 3

Cases from units screened at 24 h Three of our recent cases (“breakthroughs”) were in apheresis units screened for bacterial contamination at 24 h: Screening method Age issued (days) Culture at issue Quantitation (CFU/mL) Plate culture 4 Serratia marcescens 8.5 X 107 eBDS 3 Staphylococcus aureus 2.3 X 103 BACT/Alert 5 Coagulase-negative staphylococcus 1.3 X 107

Validation studies of at issue detection methods These studies are time-consuming and much more difficult to perform than studies of early culture methods Inoculating platelets with low numbers of bacteria is difficult to achieve technically – 10-50 CFU/mL is the lowest range that is technically reproducible It is difficult to work with some species at low inocula as units often self-sterilize (e.g., Pseudomonas aeruginosa, coagulase-negative staphylococci) Validation studies should concentrate on the most virulent pathogens -Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus cereus, Streptococcus bovis, and single most common contaminant, coagulase negative staphylococci Species that have only been reported once (e.g., Clostridium perfringens), have never been reported (e.g., Clostridium difficile), or are very rare and of very low virulence (e.g., Proprionebacterium acnes) do not need, in our opinion, to be studied

Conclusions Bacterial contamination of platelets is a significant problem Contamination rate of older RPD and SDP units is around 1:2,000 units, with rate being 5-fold higher in RDP pools Rate of transfusion reactions associated with bacterial contamination, based on all transfusions, is at least 1:16,000 RPD and SDP units, with rate being 5-fold higher in RDP pools Since introduction of new rules for limiting contamination in March 2004, 3/10 instances were “breakthrough” cases in apheresis units screened at 24-h (Serratia marcescens 8.5 x 107 CFU/mL, Staph. aureus 1.0 x 103 CFU/mL; CONS 1.3 x 107 CFU/mL) Based on our experience over 15 years, an at issue detection system with a sensitivity of : 105 CFU/ml would have detected 10/11 serious reactions, and 15/19 (79%) with any reaction 104 CFU/ml would have detected all 11 serious reactions, and 16/19 (84%) with any reaction 103 CFU/ml would have detected 30/38 (79%) cases, including all serious reactions and 18/19 (95%) reactions of any kind

The bottom line ….. An at issue detection system with a sensitivity of: 105 CFU/ml would have prevented all fatal reactions, 91% of serious reactions, and 79% of all reactions 103 CFU/ml would have prevented all serious reactions, 79% of all cases and 95% of all reactions

Thank you